- Home
- XGN vs ICMB Comparison
XGN vs ICMB Comparison
Compare XGN & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XGN | ICMB |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.9M | 38.9M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | XGN | ICMB |
|---|---|---|
| Price | $6.04 | $2.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $13.67 | N/A |
| AVG Volume (30 Days) | ★ 295.4K | 31.8K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | ★ 19.26% |
| EPS Growth | N/A | ★ 31.51 |
| EPS | N/A | ★ 0.38 |
| Revenue | ★ $63,599,000.00 | $17,931,778.00 |
| Revenue This Year | $21.76 | N/A |
| Revenue Next Year | $15.63 | $4.75 |
| P/E Ratio | ★ N/A | $7.04 |
| Revenue Growth | ★ 14.08 | N/A |
| 52 Week Low | $2.67 | $2.46 |
| 52 Week High | $12.23 | $3.47 |
Technical Indicators
Market Signals| Indicator | XGN | ICMB |
|---|---|---|
| Relative Strength Index (RSI) | 26.73 | 36.64 |
| Support Level | $5.84 | $2.66 |
| Resistance Level | $6.34 | $2.73 |
| Average True Range (ATR) | 0.33 | 0.08 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 13.79 | 4.55 |
Price Performance
Historical ComparisonAbout XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.